Efficacy and Safety of Adjunctive Recombinant Human Interleukin-2 for Patients with Pulmonary Tuberculosis: A Meta-Analysis

Table 2

Details of quality evaluation via the Cochrane’s risk of bias tool.

Study	Random sequence generation	Allocation concealment	Blinding in performance	Blinding in outcome detection	Incomplete outcome data	Reporting bias	Other bias
Johnson 1997	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk	Unclear
Li 2003	Unclear	Unclear	Unclear	Unclear	Low risk	Low risk	Low risk
Johnson 2003	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk
Liang 2003	Low risk	Unclear	Unclear	Unclear	Low risk	Low risk	Low risk
Chu 2003	Unclear	Unclear	Unclear	Unclear	Low risk	Low risk	Low risk
Xu 2004	Unclear	Unclear	Unclear	Unclear	Low risk	Low risk	Low risk
Zhang 2005	Unclear	Unclear	Unclear	Unclear	Low risk	Low risk	Low risk
Yu 2008	Unclear	Unclear	Unclear	Unclear	Low risk	Low risk	Low risk
Song 2011	Unclear	Unclear	Unclear	Unclear	Low risk	Low risk	Low risk
Xue 2012	Unclear	Unclear	Unclear	Unclear	Low risk	Low risk	Low risk
Tang 2013	Unclear	Unclear	Unclear	Unclear	Low risk	Low risk	Low risk
Cui 2014	Low risk	Unclear	Unclear	Unclear	Low risk	Low risk	Low risk
Shen 2015	Unclear	Unclear	Unclear	Unclear	Low risk	Low risk	Low risk
Liang 2015	Low risk	Unclear	Unclear	Unclear	Low risk	Low risk	Low risk
Tian 2017	Unclear	Unclear	High risk	High risk	Low risk	Low risk	Low risk
Chen 2019	Unclear	Unclear	Unclear	Unclear	Low risk	Low risk	Low risk
Nie 2022	Low risk	Unclear	Unclear	Unclear	Low risk	Low risk	Low risk
Yan 2022	Low risk	Unclear	Unclear	Unclear	Low risk	Low risk	Low risk